Fate Therapeutics (FATE) Return on Capital Employed Growth (3y) (2016 - 2026)

Fate Therapeutics (FATE) Return on Capital Employed Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 4,893.00
4 NuCana 279.75 Bn 279.75 Bn - 2,416.00
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -494.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -649.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -3,782.00
10 Fate Therapeutics 302.48 Mn 302.48 Mn - -901.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -901.00
Dec 31, 2025 24.00
Sep 30, 2025 -655.00
Jun 30, 2025 -1,598.00
Mar 31, 2025 -2,100.00
Dec 31, 2024 -2,409.00
Sep 30, 2024 -2,151.00
Jun 30, 2024 -2,093.00
Mar 31, 2024 -2,433.00
Dec 31, 2023 -1,544.00
Sep 30, 2023 -1,843.00
Jun 30, 2023 -1,600.00
Mar 31, 2023 -242.00
Dec 31, 2022 -1,595.00
Sep 30, 2022 -795.00
Jun 30, 2022 510.00
Mar 31, 2022 892.00
Dec 31, 2021 1,056.00
Sep 30, 2021 2,864.00
Jun 30, 2021 6,104.00